. 2019 Aug 20;20(16):4067. doi: 10.3390/ijms20164067

Table 2.

Descriptive analysis of qualitative and quantitative variables.

Alive at 28/02/2018, n (%)		35 (79.6)
Median (IQR) time of survival, months		31.5 (27.5–38.5)
Localization, n (%)	Right	24 (54.6)
	Left	14 (31.8)
	Rectum	6 (13.6)
Tumor stage, n (%)	I	11 (25.6)
	II	6 (14.0)
	III	20 (46.5)
	IV	6 (14.0)
Histologic grade, n (%)	G1	2 (4.6)
	G2	30 (68.2)
	G3	12 (27.3)
Tumor infiltrating lymphocytes, n (%)		13 (31.0)
KRAS mutational status, n (%)		17 (38.6)
MiR-133a, n (%)	Down	43 (97.7)
MiR-133a, n (%)	Up	1 (2.3)
MiR-139-5p, n (%)	Down	43 (97.7)
MiR-139-5p, n (%)	Up	1 (2.3)
MiR-133b, n (%)	Down	44 (100.0)
MiR-133b, n (%)	Up	0 (0.0)
MiR-149-5p, n (%)	Down	41 (97.6)
MiR-149-5p, n (%)	Up	1 (2.4)
MiR-224-5p, n (%)	Down	6 (14.0)
MiR-224-5p, n (%)	Up	37 (86.1)
MiR-489, n (%)	Down	37 (86.1)
MiR-489, n (%)	Up	6 (14.0)
MiR-145-5p, n (%)	Down	37 (100.0)
MiR-145-5p, n (%)	Up	0 (0.0)
MiR-150-5p, n (%)	Down	35 (94.6)
MiR-150-5p, n (%)	Up	2 (5.4)

n = number; IQR = interquartile ranges.